Biotechnology firm Galapagos said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting 365 jobs in Europe, China and the U.S.
The Hong Kong stock market is seeing an unprecedented surge in listing applications from A-share companies, with ...
Claude for Life Sciences is based on Anthropic’s most powerful large language model Claude Sonnet 4.5. It’s designed to ...
After rejecting Replimune’s melanoma drug RP1 this summer, the FDA has accepted the biotech’s resubmission of an approval ...
An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks.
Investors have grown more cautious about putting their money into the inherently unpredictable drug development industry.
As scientific disinformation skyrockets, the Biotechnology Innovation Organization (BIO)—the world’s largest biotech trade ...
Biotech stocks rebound after years of weakness as M&A, lower rates and easing policy fears draw investors back to the sector.
The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...
In a Phase III trial, sacituzumab tirumotecan outperformed chemo in previously treated EGFR-mutant NSCLC patients, results presented at the ESMO Congress show.